TABLE 2.
Baseline patient demographics and descriptive statistics.
| Whole group analysis | Progressor group | Non-progressor group | P-value | |
| Participants, n | 10 | 3 | 7 | |
| Age at entry, years | 61.97 (48.66 – 71.6) | 58.65 (48.66 – 70.01) | 63.69 (55.15 – 71.60) | 0.506 |
| Sex, n | ||||
| Male | 8 | 1 | 7 | 0.007** |
| Female | 2 | 2 | 0 | |
| Disease duration at entry, months | 10.50 (1.50 – 18.55) | 2.83 (1.50 – 4.50) | 13.78 (6.90 – 18.55) | 0.024* |
| Brain volume change,% | −2.70 (−6.51 – −0.260) | −5.25 (−6.51 – −2.44) | −1.24 (−1.76 – −0.260) | <0.001*** |
| NUCOG BL | 73.65 (47.5 – 93) | 66.67 (49 – 80) | 76.64 (47.5 – 93) | 0.315 |
| NUCOG wk 52 | 65.75 (19 – 97) | 40.5 (19 – 73) | 76.57 (40.5 – 97) | 0.073^ |
| Change in NUCOG score, n | −7.90 (−41.5 – 8.00) | −26.17 (−41.5 – −7.00) | −0.07 (−17 – 8) | 0.005** |
| CSF t-tau BL, ng/mL | 152.41 (86.31 – 321.10) | 110.77 (93.56 – 127.45) | 173.24 (86.31 – 321.10) | 0.412 |
| CSF t-tau wk 52, ng/mL | 144.00 (75.41 – 216.64) | 125.02 (75.41 – 158.29) | 153.49 (95.23 – 216.64) | 0.548 |
| Change in CSF t-tau, ng/mL | −8.41 (−104.47 – 47.00) | 14.26 (−18.16 – 47.00) | −19.74 (−104.47 – 16.93) | 0.584 |
| Serum t-tau BL, ng/mL | 0.71 (0.02 – 1.87) | 0.69 (0.02 – 1.22) | 0.72 (0.11 – 1.87) | 0.648 |
| Serum t-tau wk 52, ng/mL | 0.99 (0.07 – 2.95) | 0.60 (0.17 – 1.07) | 1.19 (0.07 – 2.95) | 0.762 |
| Change in serum t-tau, ng/mL | 0.28 (−0.671 – 1.08) | −0.09 (−0.67 – 0.55) | 0.47 (−0.44 – 1.08) | 0.635 |
| Plasma t-tau BL, ng/mL | 3.33 (1.84 – 6.13) | 2.53 (1.84 – 3.22) | 3.65 (1.93 – 6.13) | 0.548 |
| Plasma t-tau wk 52, ng/mL | 3.21 (1.36 – 5.30) | 1.71 (1.36 – 2.07) | 3.81 (2.98 – 5.30) | 0.648 |
| Change in plasma t-tau, ng/mL | −0.12 (−3.16 – 3.37) | −0.82 (−1.15 – −0.49) | 0.16 (−3.16 – 3.37) | 0.855 |
| NfL BL, ng/mL | 2189.56 (683.35 – 4211.12) | 3340.67 (2454.60 – 4211.12) | 1614.00 (683.35 – 2728.84) | 0.012* |
| NfL wk 52, ng/mL | 2004.99 (665.59 – 5031.11) | 3306.20 (2330.03 – 5031.11) | 1354.39 (665.59 – 2241.94) | 0.024* |
| Change in NfL, ng/mL | −184.57 (−1050.34 – 819.99) | −34.47 (−1026.27 – 819.99) | −259.61 (−1050.34 – 63.93) | 0.211 |
Data are presented as mean (range) unless otherwise indicated. Wilcoxon signed-rank test was used to assess age, sex, and disease duration at entry between progressor and non-progressor groups. Mann–Whitney U test for the change in brain volume, cognition, and biomarkers between the progressor and non-progressor groups were conducted, and the p-value is shown in the right column. ***P-value < 0.001, **p-value < 0.01, *p-value < 0.05, ^p-value < 0.1.